Research To Practice | Oncology Videos

Latest Episodes:

Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Jul 12, 2026

Show notes

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00)
Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25)

CME information and select publications

Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft Jul 11, 2026

Show notes

Featuring an interview with Dr Jamie E Chaft, including the following topics:

Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)
Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)
Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)
Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)
Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)
Importance of clinical trials in the adjuvant setting (33:02)
Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)
Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)
Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)

CME information and select publications

Endometrial Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Jul 10, 2026

Show notes

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)
Molecular analyses in the assessment and management of endometrial cancer (07:33)

CME information and select publications

Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 09, 2026

Show notes

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
- Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
- Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
- Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information and select publications

Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 08, 2026

Show notes

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:

Introduction (00:00)
Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)
Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)
Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)
Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)
Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)

CME information and select publications

Endometrial Cancer — An Interview with Dr Floor J Backes Jul 07, 2026

Show notes

Featuring an interview with Dr Floor J Backes, including the following topics:

Overview of the treatment landscape of endometrial cancer (00:00)
Immunotherapy for advanced endometrial cancer (03:58)
Contraindications for immunotherapy (18:15)
PARP inhibitors for endometrial cancer (20:12)
Management of localized endometrial cancer (28:23)
Novel strategies under investigation for endometrial cancer (42:27)

CME information and select publications

For Oncology Nurses: Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress Jul 06, 2026

Show notes

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

Introduction (0:00)
Overview of Antibody-Drug Conjugates (ADCs) (2:07)
Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
Currently Available ADCs for Gynecologic Cancer Management (26:37)
Currently Available ADCs for Lung Cancer Management (44:07)
Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay Jul 03, 2026

Show notes

Featuring an interview with Dr Rana R McKay, including the following topics:

Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
Takeaways from the Phase III EMBARK study (19:36)
Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay (Companion Faculty Lecture) Jul 02, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics:

Overview of the current landscape of prostate cancer (0:00)
Mechanism of action of androgen deprivation therapy (ADT) (3:51)
Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18)
Real-world evidence regarding the use of relugolix (12:27)
Adverse event profile associated with ADT (18:34)
Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who receives ADT at various timepoints of treatment and is currently on relugolix (21:46)
Case: A man in his early 60s with high-risk locally advanced prostate cancer who receives various androgen receptor pathway inhibitors in addition to relugolix (28:06)

CME information and select publications

For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress Jul 02, 2026

Show notes

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:

Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications